Pharmacoeconomic analysis of tenofovir amibufenamide versus entecavir for the treatment of patients with chronic hepatitis B

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500097387

Enrollment

Unknown

Registered

2025-02-18

Start date

2024-06-01

Completion date

Unknown

Last updated

2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

entecavir group:NA

tenofovir amibufenamide group:NA

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age greater than 18 years; 2. Comply with the relevant diagnostic criteria of "Guidelines for the Prevention and Control of Chronic Hepatitis B (2022 Edition)" designated by the Chinese Medical Association Hepatology Branch and Chinese Medical Association Infectious Diseases Branch. 3. Selected patients were positive or negative for HBeAg and positive for HBV-DNA; 4. First-time use of nucleoside analogs; 5.Taking tenofovir amibufenamide or entecavir for up to 48 weeks and having complete data;

Exclusion criteria

Exclusion criteria: 1. Patients with co-morbid AIDS, viral hepatitis C, tuberculosis; 2. Missing test results to determine the effectiveness of the medication; 3. Women who are pregnant or breastfeeding;

Design outcomes

Primary

Measure	Time frame
HBV-DNA negative conversion rate;	—

Secondary

Measure	Time frame
HBeAg negative conversion rate;ALT recovery rate;Cost-Effectiveness;	—

Countries

China

Contacts

Public ContactXiuhua Zhang

The First Affiliated Hospital of Wenzhou Medical University

wzzhangxiuhua@126.com+86 577 55578055

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026